Israel - English - Ministry of Health

abic marketing ltd, israel - apomorphine hydrochloride - solution for injection / infusion - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - treatment of motor fluctuations (“on-off” phenomena) in patients with parkinson's disease which are not sufficiently controlled by oral anti-parkinson medication.

Israel - English - Ministry of Health

teva israel ltd - apomorphine hydrochloride - solution for injection - apomorphine hydrochloride 10 mg/ml - apomorphine - apomorphine - treatment of motor fluctuations (“on-off” phenomena) in patients with parkinson's disease which are not sufficiently controlled by oral anti-parkinson medication.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - apomorphine hydrochloride - oral tablet - apomorphine hydrochloride alkaloid active 6.5 mg/tb - central nervous system - dog | bitch | castrate | puppy - emetic | induce vomiting

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 4.16mg equivalent to 4 mg motelukast - chewable tablet - 4 mg - active: montelukast sodium 4.16mg equivalent to 4 mg motelukast excipient: aspartame cherry flavour 501027 ap0551 croscarmellose sodium iron oxide red magnesium stearate mannitol microcrystalline cellulose - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 5.2mg equivalent to 5 mg montelukast - chewable tablet - 5 mg - active: montelukast sodium 5.2mg equivalent to 5 mg montelukast excipient: aspartame cherry flavour 501027 ap0551 croscarmellose sodium iron oxide red magnesium stearate mannitol microcrystalline cellulose - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 10.4mg equivalent to montelukast 10 mg - tablet - 10 mg - active: montelukast sodium 10.4mg equivalent to montelukast 10 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day-time and night-time symptoms and the prevention of exercise-induced bronchospasm

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Malta - English - Medicines Authority

britannia pharmaceuticals limited - apomorphine hydrochloride - solution for infusion - apomorphine hydrochloride 5 mg/ml - anti-parkinson drugs

Malta - English - Medicines Authority

britannia pharmaceuticals limited - apomorphine hydrochloride - solution for injection - apomorphine hydrochloride 10 mg/ml - anti-parkinson drugs

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - apomorphine hydrochloride 5 mg/ml - solution for infusion - 5 mg/ml - active: apomorphine hydrochloride 5 mg/ml excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection - apomorphine is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.